These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. [A case of refractory pediatric Crohn's disease with a successful treatment by infliximab therapy]. Park SH; Jeen YT; Chun HR; Kim DI; Baeck CW; Kim YS; Chun HJ; Lee HS; Um SH; Choi JH; Kim CD; Ryu HS; Hyun JH Korean J Gastroenterol; 2005 Oct; 46(4):297-301. PubMed ID: 16247274 [TBL] [Abstract][Full Text] [Related]
5. Clinical advantages of combined seton placement and infliximab maintenance therapy for perianal fistulizing Crohn's disease: when and how were the seton drains removed? Tanaka S; Matsuo K; Sasaki T; Nakano M; Sakai K; Beppu R; Yamashita Y; Maeda K; Aoyagi K Hepatogastroenterology; 2010; 57(97):3-7. PubMed ID: 20422862 [TBL] [Abstract][Full Text] [Related]
6. Treatment of perianal fistulas in Crohn's disease by local injection of antibody to TNF-alpha accounts for a favourable clinical response in selected cases: a pilot study. Asteria CR; Ficari F; Bagnoli S; Milla M; Tonelli F Scand J Gastroenterol; 2006 Sep; 41(9):1064-72. PubMed ID: 16938720 [TBL] [Abstract][Full Text] [Related]
7. Maintenance of remission among patients with Crohn's disease on antimetabolite therapy after infliximab therapy is stopped. Louis E; Mary JY; Vernier-Massouille G; Grimaud JC; Bouhnik Y; Laharie D; Dupas JL; Pillant H; Picon L; Veyrac M; Flamant M; Savoye G; Jian R; Devos M; Porcher R; Paintaud G; Piver E; Colombel JF; Lemann M; Gastroenterology; 2012 Jan; 142(1):63-70.e5; quiz e31. PubMed ID: 21945953 [TBL] [Abstract][Full Text] [Related]
8. Clinical evolution of luminal and perianal Crohn's disease after inducing remission with infliximab: how long should patients be treated? Domènech E; Hinojosa J; Nos P; Garcia-Planella E; Cabré E; Bernal I; Gassull MA Aliment Pharmacol Ther; 2005 Dec; 22(11-12):1107-13. PubMed ID: 16305724 [TBL] [Abstract][Full Text] [Related]
9. Combined seton placement, infliximab infusion, and maintenance immunosuppressives improve healing rate in fistulizing anorectal Crohn's disease: a single center experience. Topstad DR; Panaccione R; Heine JA; Johnson DR; MacLean AR; Buie WD Dis Colon Rectum; 2003 May; 46(5):577-83. PubMed ID: 12792431 [TBL] [Abstract][Full Text] [Related]
10. Review article: efficacy of infliximab in Crohn's disease--induction and maintenance of remission. Rutgeerts PJ Aliment Pharmacol Ther; 1999 Sep; 13 Suppl 4():9-15; discussion 38. PubMed ID: 10597334 [TBL] [Abstract][Full Text] [Related]
11. Faecal diversion in the management of perianal Crohn's disease. Hong MK; Craig Lynch A; Bell S; Woods RJ; Keck JO; Johnston MJ; Heriot AG Colorectal Dis; 2011 Feb; 13(2):171-6. PubMed ID: 19863597 [TBL] [Abstract][Full Text] [Related]
12. [Acute appendicitis in a patient with perianal Crohn's disease receiving infliximab]. Szakács Z; Faluhelyi N; Fincsur A; Papp A; Vincze Á; Bajor J Orv Hetil; 2018 Mar; 159(10):405-409. PubMed ID: 29504422 [TBL] [Abstract][Full Text] [Related]
13. The efficacy of infliximab combined with surgical treatment of fistulizing perianal Crohn's disease: Comparative analysis according to fistula subtypes. Park EJ; Song KH; Baik SH; Park JJ; Kang J; Lee KY; Goo JI; Kim NK Asian J Surg; 2018 Sep; 41(5):438-447. PubMed ID: 28851611 [TBL] [Abstract][Full Text] [Related]
14. Infliximab in treatment of Crohn's disease: the Milan experience. Ardizzone S; Colombo E; Maconi G; Bollani S; Manzionna G; Petrone MC; Bianchi Porro G Dig Liver Dis; 2002 Jun; 34(6):411-8. PubMed ID: 12132788 [TBL] [Abstract][Full Text] [Related]
15. Clinical use of Infliximab in Crohn's disease: the Edinburgh experience. Arnott ID; McDonald D; Williams A; Ghosh S Aliment Pharmacol Ther; 2001 Oct; 15(10):1639-46. PubMed ID: 11564005 [TBL] [Abstract][Full Text] [Related]
16. [Indications and results of infliximab in Crohn's disease]. Karoui S; Boubaker J; Filali A Tunis Med; 2004 Dec; 82(12):1057-63. PubMed ID: 15822505 [TBL] [Abstract][Full Text] [Related]
17. Infliximab in the surgical management of complex fistulating anal Crohn's disease. Talbot C; Sagar PM; Johnston MJ; Finan PJ; Burke D Colorectal Dis; 2005 Mar; 7(2):164-8. PubMed ID: 15720356 [TBL] [Abstract][Full Text] [Related]
18. Infliximab in the treatment of Crohn's disease: a user's guide for clinicians. Sandborn WJ; Hanauer SB Am J Gastroenterol; 2002 Dec; 97(12):2962-72. PubMed ID: 12492177 [TBL] [Abstract][Full Text] [Related]
19. Response to infliximab is related to disease duration in paediatric Crohn's disease. Lionetti P; Bronzini F; Salvestrini C; Bascietto C; Canani RB; Dé Angelis GL; Guariso G; Martelossi S; Papadatou B; Barabino A Aliment Pharmacol Ther; 2003 Aug; 18(4):425-31. PubMed ID: 12940928 [TBL] [Abstract][Full Text] [Related]
20. Infliximab heals intestinal inflammatory lesions and restores growth in children with Crohn's disease. Borrelli O; Bascietto C; Viola F; Bueno de Mesquita M; Barbato M; Mancini V; Bosco S; Cucchiara S Dig Liver Dis; 2004 May; 36(5):342-7. PubMed ID: 15191204 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]